Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)
CUSIP: 87650L103
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 42,450,857
- Total 13F shares
- 40,066,753
- Share change
- +736,134
- Total reported value
- $1,089,006,566
- Put/Call ratio
- 2132%
- Price per share
- $27.18
- Number of holders
- 147
- Value change
- +$6,596,629
- Number of buys
- 91
- Number of sells
- 75
Quarterly Holders Quick Answers
What is CUSIP 87650L103?
CUSIP 87650L103 identifies TARS - Tarsus Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87650L103:
Top shareholders of TARS - Tarsus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
13F
3/4/5
|
Company · 10%+ Owner |
7.7%
|
3,272,341
|
$118,949,595 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
6.7%
|
2,863,406
|
$104,084,808 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
6.2%
|
2,652,680
|
$96,424,917 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
5.7%
|
2,398,918
|
$87,200,670 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
5.3%
|
2,254,797
|
$81,961,871 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
5%
|
2,139,102
|
$77,756,358 | — | 31 Mar 2024 | |
| COWEN AND COMPANY, LLC |
13F
|
Company |
5%
|
2,122,530
|
$77,153,965 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.3%
|
1,826,632
|
$66,398,072 | — | 31 Mar 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
4.2%
|
1,787,527
|
$64,976,606 | — | 31 Mar 2024 | |
| Vivo Capital IX, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,469,001
|
$49,380,020 | — | 05 May 2022 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
3.1%
|
1,330,938
|
$48,379,596 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
3.1%
|
1,296,416
|
$47,124,722 | — | 31 Mar 2024 | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND |
13F
|
Company |
2.1%
|
898,000
|
$32,642,300 | — | 31 Mar 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.9%
|
793,829
|
$28,855,684 | — | 31 Mar 2024 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
1.7%
|
727,891
|
$26,458,838 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
717,090
|
$26,066,222 | — | 31 Mar 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
1.7%
|
710,277
|
$25,818,568 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
629,692
|
$22,892,539 | — | 31 Mar 2024 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
1.5%
|
627,430
|
$22,807,081 | — | 31 Mar 2024 | |
| BOONE CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.4%
|
609,104
|
$22,140,930 | — | 31 Mar 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.4%
|
590,000
|
$21,446,500 | — | 31 Mar 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
1.3%
|
565,550
|
$20,557,743 | — | 31 Mar 2024 | |
| Tetragon Partners GP Ltd |
13F
|
Company |
1.1%
|
450,000
|
$16,357,500 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1%
|
424,830
|
$15,442,570 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.82%
|
347,683
|
$12,640,000 | — | 31 Mar 2024 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.71%
|
300,000
|
$10,905,000 | — | 31 Mar 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.64%
|
272,498
|
$9,905,302 | — | 31 Mar 2024 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.64%
|
270,758
|
$9,842,053 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.58%
|
247,177
|
$8,984,884 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.54%
|
229,492
|
$8,342,035 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.53%
|
223,569
|
$8,126,733 | — | 31 Mar 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.52%
|
222,253
|
$8,078,897 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.52%
|
221,997
|
$8,069,591 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.52%
|
219,278
|
$7,970,755 | — | 31 Mar 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.51%
|
215,958
|
$7,850,000 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.48%
|
203,730
|
$7,405,586 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.46%
|
196,512
|
$7,143,211 | — | 31 Mar 2024 | |
| Allspring Global Investments Holdings, LLC |
13F
|
Company |
0.45%
|
192,303
|
$6,990,214 | — | 31 Mar 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.41%
|
175,512
|
$6,379,861 | — | 31 Mar 2024 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
0.4%
|
170,000
|
$6,179,500 | — | 31 Mar 2024 | |
| J. Goldman & Co LP |
13F
|
Company |
0.38%
|
163,347
|
$5,937,663 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.38%
|
161,163
|
$5,858,275 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
0.38%
|
160,100
|
$5,819,635 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.37%
|
156,787
|
$5,699,208 | — | 31 Mar 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.35%
|
150,321
|
$5,464,168 | — | 31 Mar 2024 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.35%
|
150,000
|
$5,453,000 | — | 31 Mar 2024 | |
| CIBC WORLD MARKETS CORP |
13F
|
Company |
0.35%
|
150,000
|
$5,452,500 | — | 31 Mar 2024 | |
| CIBC WORLD MARKET INC. |
13F
|
Company |
0.35%
|
150,000
|
$5,452,000 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.35%
|
147,826
|
$5,373,475 | — | 31 Mar 2024 | |
| Baird Financial Group, Inc. |
13F
|
Company |
0.3%
|
128,272
|
$4,662,687 | — | 31 Mar 2024 |
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) as of Q2 2024
As of 30 Jun 2024,
Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) was held by
147 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,066,753 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., Paradigm Biocapital Advisors LP, TANG CAPITAL MANAGEMENT LLC, COWEN AND COMPANY, LLC, VANGUARD GROUP INC, MORGAN STANLEY, Frazier Life Sciences Management, L.P., JENNISON ASSOCIATES LLC, and PERCEPTIVE ADVISORS LLC.
This page lists
147
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
155
Q2 2024 holders
147
Holder diff
-8
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.